Showing 831-840 of 1350 results for "".
- Palm Phytonutrients To Be Displayed at Expohttps://practicaldermatology.com/news/palm-phytonutrients-be-displayed-expo/2462663/As the cosmeceutical market continues to expand, so does consumer interest in learning more about the key active ingredients in cosmeceutical products and how they work, according to a press release from palm phytonutrient manufacturer PhytoGaia. PhytoGaia, a manufacturer of palm phytonut
- Study: Pembrolizumab Shows Efficacy in Japanese Patients with Advanced Melanomahttps://practicaldermatology.com/news/study-pembrolizumab-shows-efficacy-japanese-patients-advanced-melanoma/2462539/A recent analysis of the phase 1b KEYNOTE-041 trial indicated effectiveness and tolerability of pembrolizumab in Japanese patients with advanced melanoma. Researchers conducted the study over a 12-month period. The study evaluated pembrolizumab's long-term efficacy and safety in individua
- LEO Foundation Plans to Double Philanthropic Grants for Skin Diseaseshttps://practicaldermatology.com/news/leo-foundation-plans-double-philanthropic-grants-skin-diseases/2462483/Reporting a successful year in 2023, the LEO Foundation has announced its goals and aspirations out to 2030, including the awarding of a prestigious 5 million Danish kroner prize to a distinguished researcher in Denmark contributing to skin research. The Foundation plans to double its phi
- Lebrikizumab Linked with Improvement in Patients with AD and Skin of Colorhttps://practicaldermatology.com/news/lebrikizumab-linked-with-improvement-in-patients-with-atopic-dermatitis-and-skin-of-color/2462431/New first-of-its-kind research presented at the American Academy of Dermatology 2024 Annual Meeting suggests that lebrikizumab showed efficacy in patients with skin of color who had atopic dermatitis (AD). “People with skin of color are disproportionately affected by AD, often experienci
- Alumis Closes $259 Million Financing to Help Launch Phase 3 Psoriasis Trial for Lead Asset ESK-001https://practicaldermatology.com/news/alumis-closes-259-million-financing-to-help-launch-phase-3-psoriasis-trial-for-lead-asset/2462267/In this year's largest privite biotech fundraise to date, Alumis announced $259 million Series C financing to initiate pivotal phase 3 clinical trials for its lead candidate ESK-001, a highly selective allosteric tyrosine kinase 2 (TYK2) inhibitor, in moderate to severe pl
- Nutrafol® Announces Expansion Into Skin with Daily Acne Supplementhttps://practicaldermatology.com/news/hair-health-leader-nutrafol-expands-into-skin/2462253/Hair health leader Nutrafol has announced an expansion into the skin space with the launch of its new product, Nutrafol Skin. According to the manufacturer, the first-of-its-kind once-daily supplement for women 18 years of age and older who experience mild to moderate acne. A
- Biofrontera Announces Restructuring of Supply Agreement, Reduces Ameluz Transfer Pricinghttps://practicaldermatology.com/news/biofrontera-inc-announces-private-placement-of-up-to-160-million-priced-at-market-per-nasdaq-rules/2462246/Biofrontera has announced a restructuring of agreements with its former parent company, Biofrontera AG, aimed at enhancing long-term profitability. As a result, the transfer price of its leading product, Ameluz, indicated for the treatment of actinic keratosis, will be slashed from 50% to 25% for
- JAK-STAT Inhibitors Not Linked with Significant Increase in Cardiovascular Eventshttps://practicaldermatology.com/news/short-term-cardiovascular-complications-in-dermatology-patients-receiving-jak-stat-inhibitors/2462236/A new systematic review looking at the potential cardiovascular risks associated with Janus kinase–signal transducer and activator of transcription inhibitors (JAK-STATi) showed no safety signals in the short term. The findings bring a nuanced perspective on the safety profile of systemic
- Upadacitinib in Atopic Dermatitis: New Safety Data Encourages Practitioners and Patientshttps://practicaldermatology.com/news/long-term-safety-of-upadacitinib-in-atopic-dermatitis-5-year-analysis-unveils-encouraging-results/2462210/A recent analysis reveals that upadacitinib, an oral Janus kinase 1 (JAK1) inhibitor, maintains its safety profile over a span of 5 years, aiding individuals
- Shmuel Gov Named COO of Strata Skin Scienceshttps://practicaldermatology.com/news/shmuel-gov-named-coo-at-strata-skin-sciences/2462169/Shmuel Gov is the new Chief Operating Officer (COO) of STRATA Skin Sciences. The Company has also hired Dr. Amandeep Kaur as Vice President of Marketing and Business Growth. Mr. Gov brings more than 30 years of industry experience in medical device business, operations, and R&